Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira

National Institute for Health and Care Excellence NICE logo

NICE backs use of anti-cholesterol drug Ezetrol

Draft guidance reflects 'greater emphasis on managing CVD risk'

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

National Institute for Health and Care Excellence NICE logo

NICE to speed up adoption of health technologies

Launches new Office for Market Access

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

National Institute for Health and Care Excellence NICE logo

NICE gives nod to Gilead’s Zydelig

First class of drug to be recommended for leukaemia

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links